- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
PREZCOBIX™ (darunavir/cobicistat) Approved in the U.S. for the Treatment of Adults Living With HIV-1
Combined Fixed-Dose Tablet of Darunavir and Cobicistat Can Help Reduce Number of Pills in a Combination Antiretroviral Treatment Regimen
U.S. FDA Approves IMBRUVICA® (ibrutinib) for the Treatment of Waldenström’s Macroglobulinemia: First FDA-Approved Therapy for This Disease
Approval represents fourth indication for IMBRUVICA in the U.S.
Johnson & Johnson Announces Formation of Ebola Vaccine Development Consortia, Gains Funding from Innovative Medicines Initiative
Consortia funded through the IMI Ebola+ Programme Supported by the European Commission Brings together London School of Hygiene and Tropical Medicine, Inserm, University of Oxford, Le Centre Muraz, Bavarian Nordic A/S, Vibalogics, the Grameen Foundation and World Vision of Ireland with Janssen Pharmaceutical Companies to help accelerate Ad26 – MVA Ebola vaccine development and patient education
Real-World Data Published in Clinical Cardiology Show Consistent Safety Performance of Once-Daily XARELTO®
Findings Add to Rigorous Post-Marketing Safety Program for XARELTO® in Routine Clinical Practice
Johnson & Johnson Announces Start of Phase 1 Clinical Trial of Ebola Vaccine Regimen
Company Has Produced More Than 400,000 Vaccine Regimens for Use in Large-Scale Clinical Trials by April 2015
Janssen Submits New Drug Application to U.S. FDA for Three-Month Paliperidone Palmitate
First Long-Acting Treatment to be Used Four Times a Year for Schizophrenia in Adults
Real-World Data Presented at the American Heart Association (AHA) Scientific Sessions Underscore Hospitalization and Outpatient Cost-Savings for XARELTO® Compared to Standard of Care
Findings Add to Existing Data Showing XARELTO® Cost-Savings Value Across Indications
Johnson & Johnson Announces Completion Of Alios Biopharma Acquisition
Further Strengthens Existing Pipeline to Address Infectious Diseases